➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Express Scripts
Boehringer Ingelheim
Johnson and Johnson
Merck

Last Updated: August 1, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,801,881


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,801,881 protect, and when does it expire?

Patent 9,801,881 protects IMBRUVICA and is included in two NDAs.

This patent has forty-two patent family members in seventeen countries.

Summary for Patent: 9,801,881
Title:Use of inhibitors of bruton's tyrosine kinase (BTK)
Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
Inventor(s): Buggy; Joseph J. (Mountain View, CA), Elias; Laurence (Berkeley, CA), Fyfe; Gwen (San Francisco, CA), Hedrick; Eric (Summit, NJ), Loury; David J. (Incline Village, NV), Mody; Tarak D. (Sunnyvale, CA)
Assignee: Pharmacyclics LLC (Sunnyvale, CA)
Application Number:14/091,196
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,801,881
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 9,801,881

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-002 Dec 20, 2017 AB RX Yes No ⤷  Try it Free ⤷  Try it Free TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA ⤷  Try it Free
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-001 Nov 13, 2013 AB RX Yes Yes ⤷  Try it Free ⤷  Try it Free TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA ⤷  Try it Free
Pharmacyclics Inc IMBRUVICA ibrutinib TABLET;ORAL 210563-001 Feb 16, 2018 RX Yes No ⤷  Try it Free ⤷  Try it Free TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA ⤷  Try it Free
Pharmacyclics Inc IMBRUVICA ibrutinib TABLET;ORAL 210563-001 Feb 16, 2018 RX Yes No ⤷  Try it Free ⤷  Try it Free TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION ⤷  Try it Free
Pharmacyclics Inc IMBRUVICA ibrutinib TABLET;ORAL 210563-002 Feb 16, 2018 RX Yes No ⤷  Try it Free ⤷  Try it Free TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,801,881

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2011261185 ⤷  Try it Free
Australia 2015275321 ⤷  Try it Free
Australia 2018204179 ⤷  Try it Free
Australia 2020202752 ⤷  Try it Free
Brazil 112012030625 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
McKesson
Boehringer Ingelheim
Johnson and Johnson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.